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Key message points: 
• While genital HPV infection is often acquired through intimate sexual contact, other non-
sexual transmission routes are possible including autoinoculation. 
• Comprehensive evaluation of every case of ano-genital warts in a child is necessary to 
determine if child sexual abuse (CSA) may have occurred. 
• Molecular HPV genotyping is not currently informative for cases for CSA. 
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Why undertake this review? 
At the Scottish HPV Reference laboratory we deliver HPV testing for epidemiological, clinical and 
research work-streams. We also serve as a hub for enquiries relating to HPV, HPV testing and the 
consequences of infection.  Enquiries are varied but have included those around the detection and 
implications of HPV infection in childhood and the rationale/justification for HPV testing in cases of 
suspected child sexual abuse (CSA).  Given these enquiries, the sensitive nature of the issues and 
legal implications associated, we took the opportunity to review the evidence on the origins and 
implications of HPV infection in children and to highlight any key knowledge gaps. To this end we 
provide a summary document that will hopefully be of use to clinicians.  
How can children acquire HPV? 
Human papillomavirus (HPV) is a common epitheliotropic virus that can be transmitted via skin-to-
skin contact. One of the more common clinical manifestations of anogenital HPV infection is genital 
warts, which has a peak prevalence in young adults aged 20-25 years [1]. However, ano-genital warts 
can also arise in children, which raises questions and concerns around potential sexual abuse.  
As genital HPV infection is often acquired through intimate contact, sexual abuse can of course 
provide a transmission route with or without penetration.  However, there are other mechanisms of 
HPV transmission. Vertical transmission (from mother to baby) can occur transplacentally; HPV has 
been found in amniotic fluid and cord-blood, or during passage through the birth canal. Horizontal 
transmission of HPV can occur via autoinoculation i.e. the child has cutaneous warts and transmits 
virus to another of his/her body parts or through heteroinoculation where the carer/close contact 
has warts and transmits virus to child. 
Reports on vertical transmission of HPV between the infants and their mothers conducted between 
1997 to 2009 are summarised in Table 1, [2, 6, 7, and 8]. Differences in study design, case definition 
of HPV positivity (e.g. clinical evidence or serological/molecular evidence) make the generation of a 
consensus statement on the rate of vertical transmission challenging.  However the existing 
evidence indicates that in mothers with clinical signs of HPV infection (i.e. warts) vertical 
transmission may be higher than in those with asymptomatic infection.  This said, with respect to 
asymptomatic women, Castellsague found children born to cervical HPV-DNA positive mothers were 
significantly more likely to be HPV positive at the 6 week visit post partum compared to infants born 
to HPV negative mothers (p=0.02), [2]. Moreover, Merckx published a meta-analysis of, which 
included 20 studies or 3128 mother-child pairs. From the data, they found significant heterogeneity 
among different studies, and a relative risk increase of 33% [3]. 
 
 
 
 
 
Table 1. Rates of vertical transmission, mother – infant HPV concordance and persistence of HPV in infant 
samples. 
Study, Year 
HPV status in 
mothers 
HPV status in infant 
Concordance  
Infant - Mother 
Persistence of HPV 
positivity (>2 samples 
positive) only 18 
samples tested >2 
[2] Castellsague 
(2009)a 
66 positive 
77 negative 
13 (19.7%) 
13 (16.9%) 
5/16 (31%) samples 
(315) 
2/18 (11%) 
[6] Marais (2007)b 
 
100 positive 
23/111infants 
(20.7%) 
7/23 (30.4%) N/A 
[7] Manns (1999)c 
23 positive 
(only looked for HPV 
16 antibodies) 
75 negative 
1/23 (4%) 
(only tested at 2 
years, retrospectively 
looked at birth) 
2/75 (2.7%) 
N/A 
1 (4%) 
(negative at 5 and 11 
months) 
2 (2.7%) 
[8] Puranen (1997)d 
41 positive 
18 clinical signs of 
HPV 
39/105 (37%) 
15/18 (83%) 
29/42 (69%) 
13/18 (72%) N/A 
a)  HPV DNA was detected from HPV transmission from 66 HPV-positive and 77 HPV-negative pregnant women 
and their infants. b) Prevalence of anti-HPV-16, HPV-11 and HPV-18 IgG antibodies was analysed in mothers 
and their children in an attempt to identify evidence of HPV trans-mission from mother to child.  c) In this 
report they evaluated the possible mother to infant transmission of HPV, using a validated serologic assay to 
detect antibody responses to HPV 16. d) Authors evaluated the mother-infant transmission in 106 infants born 
by vaginal delivery or by caesarean section and their 105 mothers using PCR.  
 
How common is HPV in children? 
There is a paucity of data on the prevalence of HPV infection in children and the estimates that exist 
vary widely. From a UK perspective, O’Leary [4] conducted a study in schools and further education 
colleges, which involved the molecular testing of urine samples and showed the weighted 
prevalence of any HPV to be 1.1% for 11-14 year old females compared to 15.4% for 15-18 year olds.  
Consistent with the findings of O Leary, Dunne noted that the younger the child the lower the 
prevalence i.e. in children under 7 years of age the prevalence was 0.4% compared to 3.3% in 
children over 7 years of age [5].  
What is the frequency of CSA in children with ano-genital warts? 
There are relatively few studies in which the frequency of child sexual abuse in children presenting 
with ano-genital warts have been comprehensively assessed (Table 2). Three studies performed 
between 1996 to 2006 ranged in size from 17- to just 72 patients. De Jesus concluded that ano 
genital warts in children > 5 years of age should raise a strong suspicion of sexual abuse, [9]. In 2006, 
Sinclair found that children compared to children less than 4 years of age, children aged 4-8 years 
with ano-genital warts had a 2.9x increased risk of child sexual abuse compared to children < 4 years 
of age, and those > 8 years of age had a 12.1x increased risk of child sexual abuse, [10]. In the same 
year Marcoux reported that the mean age of onset of wart manifestation in childhood was 3 years 9 
months (28% <2 yrs and 62% 2-6yrs) and in 25% (18/72) child sexual abuse was confirmed or 
suspected, [11]. 
Table 2. Summary of above studies looking at the frequency of child sexual abuse in children presenting with 
ano-genital warts. 
 
Study, Year 
Number of children 
with confirmed 
child sexual abuse 
Age of children with 
confirmed child sexual 
abuse 
Number of 
children with 
no child 
sexual abuse 
Age of children with no 
child sexual abuse 
[9] De Jesus 
(2001) 
8/17 (49%) >4 years 5/17 (29%) <3 years 
[10] Sinclair 
(2006) 
17/55 (31%) 
0 - < 2 years 
5/17(29%) 2-4 years 
5/17(29%) 4-8 years 
7/17(42%) >8 years 
38/55 (69%) 
9/9 < 2 years 
17/38 (45%) 2-4years 
9/38(24%) 4-8years 
3/38(8%) >8years 
[11] Marcoux 
(2006) 
 
18/72 (25%) 
Only age data for 
16/18 
 
0 - < 1 years 
9/16 (56%) 1-4years 
5/16(31%) 4-8years 
2/16(13%) >8years 
54/72 (75%) 
Only age data 
for 43/54 
10(23%) <1year 
28(65%) 1-4years 
5(12%) 4-8years 
0 > 8 years 
 
 
What to consider if the child presents anogenital warts? 
Given that HPV infection can be acquired via non sexual mechanisms, all methods of transmission 
should be considered in addition to possible abuse. It seems reasonable that at least a group of 
children <2-3 years will have developed anogenital warts secondary to vertical transmission given 
that the duration of HPV infection can last 2-4 years after acquisition. As described above evidence 
indicates that increasing age is inversely associated with the likelihood of vertical (rather than 
sexual) transmission.  However, there is no clear or evidenced  age “cut off” which is indicative of 
abuse hence evaluation on a case by case basis is necessary to inform the decision as to whether a 
CSA investigation is required.   
 
Is molecular HPV testing informative when considering CSA? 
No. Genital warts are diagnosed clinically and laboratory confirmation of HPV status does not add 
value nor would it inform treatment decisions.  Additionally molecular testing and genotyping of 
HPV in children is unhelpful in confirming/determining whether abuse has occurred due to (1) the 
transient nature of HPV infection, (2) the observed lack of concordance of HPV genotype in children 
(even where sexual abuse has been confirmed) and the carer and (3) technical issues/challenges 
with testing superficial samples. 
What guidelines exist that relate to the management of genital warts in children? 
Various guidelines related to genital wart diagnosis and child sexual abuse cases are available from 
different organisations, including WHO, BASHH and the Royal College of Paediatricians. Although 
some of these guidelines are relative elderly, they converge on the point there is limited evidenced 
for the use of molecular HPV testing in children to gain insight into CSA. 
What additional research/work is needed? 
Contemporary parent to child transmission studies that provide a better understanding of the 
detailed natural history of HPV acquisition, clearance and clinical manifestation(s) in children, would 
help determine a “background” level of genital HPV carriage in children and potentially identify non-
sexual risk factors for transmission. Such studies would also provide more precise estimates of the 
development of ano-genital warts secondary to vertical transmission of HPV. Additionally, 
prophylactic HPV vaccination has already demonstrated a significant impact on adult diagnoses of 
genital warts and is likely to exert an influence in children over time both directly and indirectly 
through herd immunity. 
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